trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7] oxepino [4,5-c] pyrrol-1-one | 65621-78-5

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噁庚英
• 英文名称: trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7] oxepino [4,5-c] pyrrol-1-one
• 英文别名: 1H-Dibenz[2,3:6,7]oxepino[4,5-c]pyrrole, 5-chloro-2,3,3a,12b-tetrahydro-2-methyl-, cis-；(2R,6S)-9-chloro-4-methyl-13-oxa-4-azatetracyclo[12.4.0.02,6.07,12]octadeca-1(18),7(12),8,10,14,16-hexaene
• CAS: 65621-78-5
• 化学式: C₁₇H₁₆ClNO
• 分子量: 285.773
• InChiKey: VSWBSWWIRNCQIJ-LSDHHAIUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  阿塞那平杂质 在 碘 、 magnesium 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 2.92h， 以82%的产率得到trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz [2,3:6,7] oxepino [4,5-c] pyrrol-1-one
  参考文献：
  名称：

  Intermediate compounds for the preparation of trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1h-dibenz[2,3:6,7]oxepino[4,5-c]pyrrole

  摘要：

  公开号：

  EP1710241B1

文献信息

• Process for making asenapine
  申请人：Zhu Jie

  公开号：US20080214832A1

  公开（公告）日：2008-09-04

  Asenapine and related trans-isomer bicyclic compounds can be obtained by reducing a compound of formula (C) to preferentially form a trans-isomer compound of formula (D), followed by subsequent ring closure to form a compound of formula (B) such as asenapine.

  Asenapine和相关的顺式异构体双环化合物可以通过还原式(C)式化合物，优先形成式(D)式的顺式异构体化合物，然后通过后续的环闭合反应形成式(B)式化合物，如asenapine。
• US7875729B2
  申请人：——

  公开号：US7875729B2

  公开（公告）日：2011-01-25
• [EN] PROCESS FOR MAKING ASENAPINE<br/>[FR] PROCEDE DE FABRICATION D'ASENAPINE
  申请人：SYNTHON BV

  公开号：WO2008081010A1

  公开（公告）日：2008-07-10

  [EN] Asenapine and related trans-isomer bicyclic compounds can be obtained by reducing a compound of Formula (C) to preferentially form a trans-isomer compound of Formula (D), followed by subsequent ring closure to form a compound of Formula (B) such as asenapine.
  [FR] Selon l'invention, de l'asénapine et des composés bicycliquestrans-isomères associés peuvent être obtenus par réduction d'un composé de Formule (C) pour former de préférence un composé trans-isomère de Formule (D), puis par une cyclisation ultérieure destinée à former un composé de Formule (B) tel que l'asénapine.
• [EN] TRANSDERMAL COMPOSITIONS OF ASENAPINE FOR THE TREATMENT OF PSYCHIATRIC DISORDERS<br/>[FR] COMPOSITIONS TRANSDERMIQUES À BASE D'ASÉNAPINE POUR LE TRAITEMENT DE TROUBLES PSYCHIATRIQUES
  申请人：SUNIN K S

  公开号：WO2010127674A1

  公开（公告）日：2010-11-11

  The present invention relates to a pharmaceutical composition for application to the skin comprising asenapine or a pharmaceutically acceptable salt thereof and at least one of i) one or more film-forming agents, ii) one or more pharmaceutically acceptable adhesive agents, iii) one or more dermally acceptable excipients.
• [EN] A PROCESS FOR THE PREPARATION OF ASENAPINE AND NOVEL SALTS THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION D'ASÉNAPINE ET NOUVEAUX SELS DE CELLE-CI
  申请人：MEGAFINE PHARMA P LTD

  公开号：WO2013024492A2

  公开（公告）日：2013-02-21

  A process for preparation of asenapine of formula (1) or its acid addition salts; The said process comprises preparation of trans racemate of asenapine by reacting trans- 1 1-chloro-2,3,3a, 12b-tetrahydro-2-methyl-lH-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrol-l-one with mixture of aluminium chloride and lithium aluminium hydride in solvent followed by converting it into acid addition salt of asenapine followed by hydrolyzing the acid addition salt into trans racemate asenapine base and converting the asenapine base into acid addition salt. Asenapine sulphate of formula (Via) and asenapine maleate of formula (IVb) are also disclosed. The co-precipitate of acid addition salt of asenapine with a pharmaceutically acceptable excipient of formula (V); is also disclosed.